USA - NASDAQ:QNCX - US22053A1079 - Common Stock
Taking everything into account, QNCX scores 1 out of 10 in our fundamental rating. QNCX was compared to 534 industry peers in the Biotechnology industry. QNCX may be in some trouble as it scores bad on both profitability and health. QNCX has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.83% | ||
| ROE | -417.77% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.45 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.22 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5 | ||
| Quick Ratio | 5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:QNCX (10/28/2025, 1:38:05 PM)
1.71
-0.08 (-4.47%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.83 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.83% | ||
| ROE | -417.77% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.45 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 268.05% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5 | ||
| Quick Ratio | 5 | ||
| Altman-Z | -5.22 |
ChartMill assigns a fundamental rating of 1 / 10 to QNCX.
ChartMill assigns a valuation rating of 0 / 10 to QUINCE THERAPEUTICS INC (QNCX). This can be considered as Overvalued.
QUINCE THERAPEUTICS INC (QNCX) has a profitability rating of 0 / 10.
The financial health rating of QUINCE THERAPEUTICS INC (QNCX) is 2 / 10.